Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [ 18F]fluciclatide kinetics and [ 15O]H ₂O PET

摘要

Background [~(18)F]fluciclatide, a peptide ligand with high affinity for αvβ3/αvβ5 integrins, is a proposed biomarker of tumor angiogenesis. The study rationale was to perform a preliminary evaluation of the relationship between tumor [~(18)F]fluciclatide uptake and perfusion by [~(15)O]H_(2)O PET. Methods Patients with non-small cell lung cancer and melanoma underwent dynamic imaging with arterial sampling following injection of [~(15)O]H_(2)O and [~(18)F]fluciclatide. Quantification was performed using a one-tissue compartmental model for [~(15)O]H_(2)O and a two-tissue model for [~(18)F]fluciclatide at volume-of-interest level, and SUV at voxel level. Results Tumor binding potential ( k _(3)/ k _(4)ratio) of [~(18)F]fluciclatide tumor was 5.39?±?1.46, consistent with previous studies in breast cancer metastases. Voxel-by-voxel maps of [~(18)F]fluciclatide delivery strongly correlated with [~(15)O]H_(2)O-based perfusion ( p ??0.15). Conclusions Our study suggests tumor [~(18)F]fluciclatide retention is unrelated to tumor perfusion, supporting use of late (60-min) imaging protocols in patients. Electronic supplementary material The online version of this article (doi:10.1186/s13550-014-0030-x) contains supplementary material, which is available to authorized users.